Search
Clinician Ordering Portal
Scientific evidence
A cost-effectiveness analysis of a test that predicts risk of malignant progression in Barrett’s esophagus
May 2016
TissueCypher is cost-saving after five years and improves patient outcomes due to improving the effectiveness of surveillance and treatment.
Publication: Podium presentation (CN4) at ISPOR 2016, Washington DC
Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases
May 2016
To investigate the prevalence and prognostic value of SF3B1 and EIF1AX mutations in uveal melanoma (UM) patients.
Publication: Ophthalmology
A tissue systems pathology test detects a field effect associated with high grade dysplasia and esophageal cancer in Barrett’s esophagus patients
May 2016
TissueCypher better predicts presence of HGD and EAC in BE than pathologic variables, and can improve on histology to identify patients requiring therapy.
Publication: Poster presentation (Sa1257) at DDW 2016, San Diego
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Apr 2016
We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.
Publication: Nature Genetics
A novel tissue systems pathology test predicts progression in Barrett’s esophagus patients
Apr 2016
TissueCypher better predicts progression in BE than clinicopathologic variables, and can improve on histology as a method to risk stratify patients with BE.
Publication: Podium presentation (301) at DDW 2016, San Diego
A cost-effectiveness analysis of a cancer risk prediction test for patients with Barrett’s esophagus
Apr 2016
The individualized risk prediction test has the potential to improve the efficiency of endoscopic surveillance in BE and to enable early intervention as needed.
Publication: Poster presentation (Sa 1261) at DDW 2016, San Diego
A novel tissue systems pathology test predicts progression in Barrett’s esophagus patients
Apr 2016
TissueCypher better predicts progression in BE than clinicopathologic variables, and can improve on histology as a method to risk stratify patients with BE.
Publication: Podium presentation (301) at DDW 2016, San Diego
PRAME as an independent biomarker for metastasis in uveal melanoma
Mar 2016
Uveal melanoma (UM) can be classified by gene expression profiling (GEP) into Class 1 (low metastatic risk) and Class 2 (high metastatic risk), the latter being strongly associated with mutational inactivation of the tumor suppressor BAP1. Nevertheless, a small percentage of Class 1 tumors give rise to metastatic disease. The purpose of this study was to identify biomarkers of metastasis in Class 1 tumors.
Publication: Clinical Cancer Research
Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
Jan 2016
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Dec 2015
Next generation sequencing of uveal melanoma (UM) samples has identified a number of recurrent oncogenic or loss-of-function mutations in key driver genes including: GNAQ, GNA11, EIF1AX, SF3B1 and BAP1. To search for additional driver mutations in this tumor type we carried out whole-genome or whole-exome sequencing of 28 tumors or primary cell lines. These samples have a low mutation burden, with a mean of 10.6 protein changing mutations per sample (range 0 to 53).
Publication: Oncotarget
TissueCypher: a systems biology approach to anatomic pathology
Dec 2015
A quantitative, multiplexed biomarker imaging approach termed TissueCypher™ that applies systems biology to anatomic pathology.
Publication: Journal of Pathology Informatics